Evidence map›Paper›PMID 42760073›Full record

ArticleBMJ open2026

Safety of short-term non-steroidal anti-inflammatory drug use in the postoperative setting in paediatric patients with chronic kidney disease: protocol for a randomised, placebo-controlled trial.

Alice H Xiang, Catalina K Hwang, Emily Clennon, Thuytien To, Jennifer Pyrzanowski, Allyson B Calderon, Samantha Wilson, Elizabeth Shields, Gemma Beltran, Carter Sevick and 3 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06860711 (Safety of Short-term NSAID Use in the Postoperative Setting in Pediatric Patients With Chronic Kidney Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06860711 phase4recruitingnot on this map

Safety of Short-term NSAID Use in the Postoperative Setting in Pediatric Patients With Chronic Kidney Disease

TypeinterventionalSponsorUniversity of Colorado, DenverRan2025 to 2028Enrolled164ConditionsChronic Kidney Disease, Pediatric UrologyArmsNSAIDs, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alice H XiangChildren's Hospital Colorado, Aurora, Colorado, USA alicexiang22@gmail.com.ORCID http://orcid.org/0009-0005-6012-4974
Catalina K HwangChildren's Hospital Colorado, Aurora, Colorado, USA.
Emily ClennonChildren's Hospital Colorado, Aurora, Colorado, USA.
Thuytien ToSchool of Medicine, University of Colorado System, Aurora, Colorado, USA.
Jennifer PyrzanowskiChildren's Hospital Colorado, Aurora, Colorado, USA.
Allyson B CalderonResearch Outcomes in Children's Surgery, Children's Hospital Colorado, Aurora, Colorado, USA.
Samantha WilsonResearch Outcomes in Children's Surgery, Children's Hospital Colorado, Aurora, Colorado, USA.
Elizabeth ShieldsChildren's Hospital Colorado, Aurora, Colorado, USA.
Gemma BeltranChildren's Hospital Colorado, Aurora, Colorado, USA.
Carter SevickChildren's Hospital Colorado, Aurora, Colorado, USA.
Margret BockChildren's Hospital Colorado, Aurora, Colorado, USA.
Kelly T HarrisChildren's Hospital Colorado, Aurora, Colorado, USA.
Kyle O RoveChildren's Hospital Colorado, Aurora, Colorado, USA.ORCID http://orcid.org/0000-0002-2323-4139

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-steroidal anti-inflammatory drugs (NSAIDs) are a key component of multimodal analgesia in paediatric surgical care but are often avoided in patients with chronic kidney disease (CKD) due to concerns for nephrotoxicity. This trial aims to evaluate the safety of short-term NSAID use in paediatric patients with mild-to-moderate CKD undergoing inpatient urological surgery. METHODS AND ANALYSIS: This is a multicentre, double-blinded, randomised, placebo-controlled trial evaluating short-term NSAID use in paediatric patients with CKD stages 2-3a after urological surgeries requiring admission. This study is being conducted at two academic paediatric urology departments in the USA. Patients aged >18 months will be randomised 1:1 to receive ketorolac/ibuprofen or placebo for ≤5 days postoperatively. The primary outcome is acute kidney injury (AKI) as defined according to Kidney Disease: Improving Global Outcomes criteria based on serum creatinine trends and urine output. Secondary outcomes are postoperative pain scores and opioid use (reported as morphine equivalents/kg/day). Fisher's exact test will compare AKI rates between groups. The recruitment goal of 164 participants provides 80% power to detect a 20% absolute increase in AKI incidence (baseline AKI rate of 15% based on prior studies, two-sided testing). ETHICS AND DISSEMINATION: This study has been approved by the Colorado Multiple Institutional Review Board (COMIRB #24-1252) and will be conducted in accordance with institutional ethical guidelines. Written informed consent will be obtained from a parent or legal guardian for all participants, and child assent will be obtained when developmentally appropriate and required by institutional policy. Study findings will be disseminated through presentation at scientific meetings and publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT06860711.

Indexed as

Acute Kidney InjuryAnti-Inflammatory Agents, Non-SteroidalIbuprofenKetorolacPostoperative PainRenal Insufficiency, ChronicUrologic Surgical ProceduresAnalgesics, OpioidChildChild, PreschoolDouble-Blind MethodFemaleHumansInfantMaleMulticenter Studies as TopicAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalIbuprofenKetorolacPaediatric nephrologyPaediatric urologyPain management

Identifiers

PMID42760073
PMCPMC13599927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.